Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.58 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18535239 | 0.88 | POLB (1.00) | POLBNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL16148234 | 0.81 | POLB (0.54) | POLBNPC1RAB9ASMN1; SMN2NTRK1 | |
| SCHEMBL16148690 | 0.81 | POLB (0.81) | POLBNPC1RAB9ASMN1; SMN2NTRK1 | |
| SCHEMBL30902074 | 0.79 | RAB9A (0.69) | POLBNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL26113669 | 0.79 | RAB9A (0.69) | POLBNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL16369265 | 0.78 | RAB9A (0.64) | POLBNPC1RAB9ASMN1; SMN2NTRK1 | |
| SCHEMBL230157 | 0.77 | POLB (0.84) | POLBNPC1RAB9AMAPTPDE10A | |
| SCHEMBL8957996 | 0.77 | NPC1 (0.76) | POLBNPC1RAB9ASMN1; SMN2NTRK1 | |
| SCHEMBL9015206 | 0.76 | RAB9A (0.79) | POLBNPC1RAB9ASMN1; SMN2NTRK1 | |
| SCHEMBL16147271 | 0.76 | NTRK1 (0.64) | POLBNPC1RAB9ASMN1; SMN2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | POLB 1354/4885NPC1 4173/4885RAB9A 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.